ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
August 21, 2023 16:12 ET
|
ProMIS Neurosciences Inc.
At-the-Market Fundraise supports Company through several potentially value-creating milestones and beyond TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 21, 2023 (GLOBE NEWSWIRE) -- ProMIS...
ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
July 17, 2023 07:00 ET
|
ProMIS Neurosciences Inc.
New findings highlight that PMN310 was able to target toxic amyloid-beta oligomers more selectively than other amyloid-beta-directed antibodies which were generated using synthetic oligomersRationally...
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
June 30, 2023 08:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 30, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMN), a biotechnology company focused on the generation and development...
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
May 15, 2023 17:00 ET
|
ProMIS Neurosciences Inc.
Received FDA clearance for investigational new drug (IND) application for lead therapeutic candidate, PMN310, in Alzheimer’s diseasePresented preclinical data supporting target identification and...
ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
May 08, 2023 09:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 08, 2023 (GLOBE NEWSWIRE) -- In preclinical studies, PMN310 demonstrated the ability to selectively target and protect against pathogenic Aβ...
Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease
April 25, 2023 17:00 ET
|
ProMIS Neurosciences Inc.
Findings support Aβ vaccine candidate consisting of conformational B cell epitope of Aβ oligomers conjugated to a carrier protein as a potential strategy for preventing Alzheimer’s disease progression...
ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting
April 24, 2023 07:30 ET
|
ProMIS Neurosciences Inc.
Lead therapeutic candidate for Alzheimer’s disease, PMN310, demonstrated selective binding and protection against toxic amyloid-beta oligomersPreclinical data support misfolded RACK1 as a potential...